Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation
Proceedings of the National Academy of Sciences · 31.03.2026 · 123 (13)
DOI: 10.1073/pnas.2528398123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 23.03.2026. Verfasst von Kannan Balakrishnan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987. Hauptthemen laut MEDLINE: Sumoylation, Exoribonucleases, Tripartite Motif Proteins, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Foundation for the National Institutes of Health (FNIH), Cancer Prevention and Research Institute of Texas (CPRIT).
Abstract (Originalsprache)
Members of the TRIM E3 ligase family are effectors of the host innate or intrinsic defense against various viruses; however, how specific TRIM proteins antagonize coronavirus infection is still largely elusive. Through an RNAi screen targeting 71 human TRIM genes, we identified multiple TRIM proteins with antiviral or proviral activity against SARS-CoV-2. TRIM32 potently restricted SARS-CoV-2 replication in a RING E3 ligase-dependent but interferon-independent manner. Mechanistically, TRIM32 binds to and SUMOylates the 3′‐to‐5′ exoribonuclease (ExoN) of Nsp14, an enzyme essential for SARS-CoV-2 replication. TRIM32-mediated Nsp14 SUMOylation at K9 and K200 inhibits RNA binding and Nsp10 cofactor recruitment, respectively, ultimately suppressing ExoN activity. Our study further revealed that Nsp14 SUMOylation by TRIM32 and its antiviral activity are broadly conserved for coronaviruses. These results identify the coronaviral Nsp14 protein as a direct target of host restriction via SUMOylation, which may uncover ways to therapeutically inhibit coronavirus infections in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL 34987.
- Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229.
ORCID-Profile: Kannan Balakrishnan, Surajit Chakraborty, Shanti Pandey, Michaela U Gack
Förderung
- Foundation for the National Institutes of Health (FNIH)
- Cancer Prevention and Research Institute of Texas (CPRIT)
Zitieren
APA
Balakrishnan, K., Chakraborty, S., Chiang, C., Stratton, C. M., Pandey, S., Tumanova, A. A., Olsen, S. K., & Gack, M. U. (2026). Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation. Proceedings of the National Academy of Sciences, 123(13). https://doi.org/10.1073/pnas.2528398123
Vancouver
Balakrishnan K, Chakraborty S, Chiang C, Stratton CM, Pandey S, Tumanova AA, et al. Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation. Proceedings of the National Academy of Sciences. 2026;123(13). doi:10.1073/pnas.2528398123
BibTeX
@article{Balakrishnan2026,
author = {Balakrishnan, Kannan and Chakraborty, Surajit and Chiang, Cindy and Stratton, Caleb M and Pandey, Shanti and Tumanova, Anna A and Olsen, Shaun K and Gack, Michaela U},
title = {Inhibition of coronaviral exoribonuclease activity by TRIM-mediated SUMOylation},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {13},
doi = {10.1073/pnas.2528398123}
}
EUVIMED